A phase IB trial of 24-hour intravenous PX-12, a thioredoxin-1 inhibitor, in patients with advanced gastrointestinal cancers

Investigational New Drugs

Volumn 31, Issue 3, 2013, Pages 631-641

  Baker, A F ^b   Adab, K N ^b   Raghunand, N ^b   Chow, H H S ^b   Stratton, S P ^b   Squire, S W ^b   Boice, M ^b   Pestano, L A ^c   Kirkpatrick, D L ^c   Dragovich, T ^a  

^a Banner MD Anderson Cancer Center   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c Oncothyreon   (United States)

Author keywords

GI Cancers; PX 12; Redox; Thioredoxin 1

Indexed keywords

1 METHYLPROPLY 2 IMIDAZOLYL DISULFIDE; 2 BUTANETHIOL; ANTINEOPLASTIC AGENT; FIBROBLAST GROWTH FACTOR 2; PX 12; THIOL DERIVATIVE; THIOREDOXIN 1; UNCLASSIFIED DRUG; VASCULOTROPIN;

ABDOMINAL DISTENSION; ADULT; ADVANCED CANCER; AGED; ANEMIA; ANXIETY; ARTICLE; ASCITES; CLINICAL ARTICLE; CONFUSION; CONSTIPATION; CONTINUOUS INFUSION; COUGHING; DIARRHEA; DIGESTIVE SYSTEM CANCER; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG INFUSION; DRUG PROTEIN BINDING; DRUG SAFETY; DYSGEUSIA; DYSPNEA; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; GASTRITIS; HUMAN; HYPERBILIRUBINEMIA; HYPOALBUMINEMIA; HYPONATREMIA; HYPOTENSION; INTERNATIONAL NORMALIZED RATIO; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; SIDE EFFECT; SMALL INTESTINE OBSTRUCTION; SWEATING; URINARY TRACT INFECTION; VOMITING; WEIGHT REDUCTION;

AGED; ANTINEOPLASTIC AGENTS; DISULFIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FIBROBLAST GROWTH FACTOR 2; GASTROINTESTINAL NEOPLASMS; HUMANS; IMIDAZOLES; INFUSIONS, INTRAVENOUS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; THIOREDOXINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84879123031     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-012-9846-2     Document Type: Article

References (31)

1. Mustacich D, Powis G (2000) Thioredoxin reductase. Biochem J 1:1-8, 346 Pt
2. Powis G, Mustacich D, Coon A (2000) The role of the redox protein thioredoxin in cell growth and cancer. Free Radic Biol Med 29:312-322
3. Grogan TM, Fenoglio-Prieser C, Zeheb R, Bellamy W, Frutiger Y, Vela E, Stemmerman G, Macdonald J, Richter L, Gallegos A, Powis G (2000) Thioredoxin, a putative oncogene product, is overexpressed in gastric carcinoma and associated with increased proliferation and increased cell survival. Hum Pathol 31:475-481
4. Hirota K, Matsui M, Iwata S, Nishiyama A, Mori K, Yodoi J (1997) AP-1 transcriptional activity is regulated by a direct association between thioredoxin and Ref-1. Proc Natl Acad Sci U S A 94:3633-3638
5. Baker A, Payne CM, Briehl MM, Powis G (1997) Thioredoxin, a gene found overexpressed in human cancer, inhibits apoptosis in vitro and in vivo. Cancer Res 57:5162-5167
6. Gallegos A, Gasdaska JR, Taylor CW, Paine-Murrieta GD, Goodman D, Gasdaska PY, Berggren M, Briehl MM, Powis G (1996) Transfection with human thioredoxin increases cell proliferation and a dominant-negative mutant thioredoxin reverses the transformed phenotype of human breast cancer cells. Cancer Res 56:5765-5770
7. Freemerman AJ, Gallegos A, Powis G (1999) Nuclear factor kappaB transactivation is increased but is not involved in the proliferative effects of thioredoxin overexpression in MCF-7 breast cancer cells. Cancer Res 59:4090-4094
8. Hayashi T, Ueno Y, Okamoto T (1993) Oxidoreductive regulation of nuclear factor kappa B. Involvement of a cellular reducing catalyst thioredoxin. J Biol Chem 268:11380-11388
9. Welsh SJ, Williams RR, Birmingham A, Newman DJ, Kirkpatrick DL, Powis G (2003) The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1alpha and vascular endothelial growth factor formation. Mol Cancer Ther 2:235-243
10. Zhou J, Damdimopoulos AE, Spyrou G, Brune B (2007) Thioredoxin 1 and thioredoxin 2 have opposed regulatory functions on hypoxia-inducible factor-1alpha. J Biol Chem 282:7482-7490
11. Welsh SJ, Bellamy WT, Briehl MM, Powis G (2002) The redox protein thioredoxin-1 (Trx-1) increases hypoxia-inducible factor 1alpha protein expression: Trx-1 overexpression results in increased vascular endothelial growth factor production and enhanced tumor angiogenesis. Cancer Res 62:5089-5095
12. Blum H, Rollinghoff M, Gessner A (1996) Expression and co-cytokine function of murine thioredoxin/adult T cell leukaemia-derived factor (ADF). Cytokine 8:6-13
13. Raffel J, Bhattacharyya AK, Gallegos A, Cui H, Einspahr JG, Alberts DS, Powis G (2003) Increased expression of thioredoxin-1 in human colorectal cancer is associated with decreased patient survival. J Lab Clin Med 142:46-51
14. Gasdaska PY, Oblong JE, Cotgreave IA, Powis G (1994) The predicted amino acid sequence of human thioredoxin is identical to that of the autocrine growth factor human adult T-cell derived factor (ADF): thioredoxin mRNA is elevated in some human tumors. Biochim Biophys Acta 1218:292-296
15. Nakamura H, Bai J, Nishinaka Y, Ueda S, Sasada T, Ohshio G, Imamura M, Takabayashi A, Yamaoka Y, Yodoi J (2000) Expression of thioredoxin and glutaredoxin, redox-regulating proteins, in pancreatic cancer. Cancer Detect Prev 24:53-60
16. Miyazaki K, Noda N, Okada S, Hagiwara Y, Miyata M, Sakurabayashi I, Yamaguchi N, Sugimura T, Terada M, Wakasugi H (1998) Elevated serum level of thioredoxin in patients with hepatocellular carcinoma. Biotherapy 11:277-288
17. Kirkpatrick DL, Kuperus M, Dowdeswell M, Potier N, Donald LJ, Kunkel M, Berggren M, Angulo M, Powis G (1998) Mechanisms of inhibition of the thioredoxin growth factor system by antitumor 2-imidazolyl disulfides. Biochem Pharmacol 55:987-994
18. Huber K, Patel P, Zhang L, Evans H, Westwell AD, Fischer PM, Chan S, Martin S (2008) 2-[(1-methylpropyl)dithio]-1H-imidazole inhibits tubulin polymerization through cysteine oxidation. Mol Cancer Ther 7:143-151
19. Welsh SJ, Williams RR, Birmingham A, Newman DJ, Kirkpatrick DL, Powis G (2003) The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1alpha and vascular endothelial growth factor formation. Mol Cancer Ther 2:235-243
20. Jordan BF, Runquist M, Raghunand N, Gillies RJ, Tate WR, Powis G, Baker AF (2005) The thioredoxin-1 inhibitor 1-methylpropyl 2-imidazolyl disulfide (PX-12) decreases vascular permeability in tumor xenografts monitored by dynamic contrast enhanced magnetic resonance imaging. Clin Cancer Res 11:529-536
21. Lieu C, Heymach J, Overman M, Tran H, Kopetz S (2011) Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis. Clin Cancer Res 17:6130-6139
22. Ng MK, Wu J, Chang E, Wang BY, Katzenberg-Clark R, Ishii-Watabe A, Cooke JP (2007) A central role for nicotinic cholinergic regulation of growth factor-induced endothelial cell migration. Arterioscler Thromb Vasc Biol 27:106-112
23. Deng ZH, Cao HQ, Hu YB, Wen JF, Zhou JH (2011) TRX is up-regulated by fibroblast growth factor-2 in lung carcinoma. APMIS 119:57-65
24. Ramanathan RK, Kirkpatrick DL, Belani CP, Friedland D, Green SB, Chow HH, Cordova CA, Stratton SP, Sharlow ER, Baker A, Dragovich T (2007) A Phase I pharmacokinetic and pharmacodynamic study of PX-12, a novel inhibitor of thioredoxin-1, in patients with advanced solid tumors. Clin Cancer Res 13:2109-2114
25. Ramanathan RK, Abbruzzese J, Dragovich T, Kirkpatrick L, Guillen JM, Baker AF, Pestano LA, Green S, Von Hoff DD (2011) A randomized phase II study of PX-12, an inhibitor of thioredoxin in patients with advanced cancer of the pancreas following progression after a gemcitabine-containing combination. Cancer Chemother Pharmacol 67:503-509
26. Tofts PS (1997) Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J Magn Reson Imaging 7:91-101
27. Rajaraman S, Rodriguez JJ, Graff C, Altbach MI, Dragovich T, Sirlin CB, Korn RL, Raghunand N (2011) Automated registration of sequential breath-hold dynamic contrast-enhanced MR images: a comparison of three techniques. Magn Reson Imaging 29:668-682
28. Ramanathan RK, Stephenson JJ, Weiss GJ, Pestano LA, Lowe A, Hiscox A, Leos RA, Martin JC, Kirkpatrick L, Richards DA: A phase I trial of PX-12, a small-molecule inhibitor of thioredoxin-1, administered as a 72-hour infusion every 21 days in patients with advanced cancers refractory to standard therapy. Invest New Drugs 2011
29. Nakamura H, Bai J, Nishinaka Y, Ueda S, Sasada T, Ohshio G, Imamura M, Takabayashi A, Yamaoka Y, Yodoi J (2000) Expression of thioredoxin and glutaredoxin, redox-regulating proteins, in pancreatic cancer. Cancer Detect Prev 24:53-60
30. Callister ME, Pinhu L, Catley MC, Westwell AD, Newton R, Leaver SK, Quinlan GJ, Evans TW, Griffiths MJ, Burke-Gaffney A (2008) PMX464, a thiol-reactive quinol and putative thioredoxin inhibitor, inhibits NF-kappaB-dependent proinflammatory activation of alveolar epithelial cells. Br J Pharmacol 155:661-672
31. Yin H, Li J, Xiong K, Wang L, Wang T, Tan Q, Fu J, Ren X, Zeng H (2011) Novel mechanism of ethaselen in poorly differentiated colorectal RKO cell growth inhibition: Simultaneous regulation of TrxR transcription, expression and enzyme activity. Differentiation 81:49-56